Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib for ctDNA-Positive HER2-Negative or TNBC Breast Cancer
NCT04915755Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of niraparib in breast cancer and triple negative breast cancer (TNBC) (4 cohorts), sponsored by GSK. Primary endpoint: Disease-Free Survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
breast cancertriple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04915755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915755.